{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:21:57Z","timestamp":1770898917468,"version":"3.50.1"},"reference-count":58,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Platelets play critical roles in hemostasis and thrombosis. While low platelet counts increase the risk of bleeding, antithrombotic drugs, including anticoagulants and antiplatelet agents, are used to treat thromboembolic events. Thus, the management of thrombosis in patients with low platelet counts is challenging with hardly any evidence available to guide treatment. Recognition of the underlying cause of thrombocytopenia is essential for assessing the bleeding risk and tailoring therapeutic options. A typical clinical scenario is the occurrence of venous thromboembolism (VTE) in cancer patients experiencing transient thrombocytopenia during myelosuppressive chemotherapy. In such patients, the severity of thrombocytopenia, thrombus burden, clinical symptoms, and the timing of VTE relative to thrombocytopenia must be considered. In clinical practice, distinct hematological disorders characterized by low platelet counts and a thrombogenic state require specific diagnostics and treatment. These include the antiphospholipid syndrome, heparin-induced thrombocytopenia (HIT) and (spontaneous) HIT syndromes, disseminated intravascular coagulation, and paroxysmal nocturnal hemoglobinuria.<\/jats:p>","DOI":"10.1055\/a-1675-7824","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:13:23Z","timestamp":1640132003000},"page":"019-028","source":"Crossref","is-referenced-by-count":4,"title":["Management of Vascular Thrombosis in Patients with Thrombocytopenia"],"prefix":"10.1055","volume":"42","author":[{"given":"Minna","family":"Voigtlaender","sequence":"additional","affiliation":[{"name":"II. Medizinische Klinik und Poliklinik, Hubertus Wald Tumorzentrum \u2013 Universit\u00e4res Cancer Center Hamburg (UCCH), Universit\u00e4tsklinikum Eppendorf, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Langer","sequence":"additional","affiliation":[{"name":"II. Medizinische Klinik und Poliklinik, Hubertus Wald Tumorzentrum \u2013 Universit\u00e4res Cancer Center Hamburg (UCCH), Universit\u00e4tsklinikum Eppendorf, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCRESAHA.117.310795","article-title":"Circulating platelets as mediators of immunity, inflammation, and thrombosis","volume":"122","author":"M Koupenova","year":"2018","journal-title":"Circ Res"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1055\/a-1344-7279","article-title":"Anticoagulation in patients with platelet disorders","volume":"41","author":"C Zaninetti","year":"2021","journal-title":"Hamostaseologie"},{"issue":"07","key":"ref3","doi-asserted-by":"crossref","first-page":"e19096","DOI":"10.1097\/MD.0000000000019096","article-title":"Immature platelet fraction: a useful marker for identifying the cause of thrombocytopenia and predicting platelet recovery","volume":"99","author":"K Jeon","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"04","key":"ref4","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"D J Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.thromres.2020.12.016","article-title":"Challenging anticoagulation cases: cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia - a case-based review of clinical management","volume":"199","author":"F Moik","year":"2021","journal-title":"Thromb Res"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/rth2.12111","article-title":"Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review","volume":"2","author":"B R Samuelson Bannow","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"B T Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref8","first-page":"171","article-title":"Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus","volume":"17","author":"M Napolitano","year":"2019","journal-title":"Blood Transfus"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11239-017-1539-4","article-title":"Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes","volume":"44","author":"B T Samuelson Bannow","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11239-018-1711-5","article-title":"Incidence and outcomes of catheter related thrombosis (CRT) in patients with acute leukemia using a platelet-adjusted low molecular weight heparin regimen","volume":"46","author":"K T Htun","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1182\/bloodadvances.2017006130","article-title":"Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation","volume":"1","author":"A Li","year":"2017","journal-title":"Blood Adv"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-021-02771-3","article-title":"Current management of cancer-associated venous thromboembolism in patients with thrombocytopenia: a retrospective cohort study","author":"A Squizzato","year":"2021","journal-title":"Intern Emerg Med"},{"issue":"47","key":"ref13","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1093\/eurheartj\/ehx531","article-title":"The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum","volume":"38","author":"C P McCarthy","year":"2017","journal-title":"Eur Heart J"},{"issue":"05","key":"ref14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ccd.26375","article-title":"SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiolog\u0131a Intervencionista)","volume":"87","author":"C Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"issue":"23","key":"ref15","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","article-title":"Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis","volume":"42","author":"E Grilz","year":"2021","journal-title":"Eur Heart J"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/a-1311-8264","article-title":"New developments in the pathophysiology and management of primary immune thrombocytopenia","volume":"41","author":"K Althaus","year":"2021","journal-title":"Hamostaseologie"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1055\/s-0039-1678739","article-title":"Diagnosing immune thrombocytopenia","volume":"39","author":"U J Sachs","year":"2019","journal-title":"Hamostaseologie"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.thromres.2019.04.016","article-title":"Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia - results from two nationwide cohorts","volume":"178","author":"C Ekstrand","year":"2019","journal-title":"Thromb Res"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/imj.14269","article-title":"Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study","volume":"49","author":"G Le Guenno","year":"2019","journal-title":"Intern Med J"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.17390","article-title":"Thrombosis in immune thrombocytopenia - current status and future perspectives","volume":"194","author":"D Swan","year":"2021","journal-title":"Br J Haematol"},{"issue":"21","key":"ref21","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"D Garcia","year":"2018","journal-title":"N Engl J Med"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"S Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2141.1996.390969.x","article-title":"Thrombocytopenia in the antiphospholipid syndrome","volume":"93","author":"M Galli","year":"1996","journal-title":"Br J Haematol"},{"issue":"04","key":"ref24","first-page":"769","article-title":"Thrombocytopenia corrected by warfarin in antiphospholipid syndrome","volume":"23","author":"H L Wisbey","year":"1996","journal-title":"J Rheumatol"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1055\/s-0035-1549841","article-title":"Right atrial thrombosis in antiphospholipid syndrome with secondary immune thrombocytopenia","volume":"4","author":"M Voigtlaender","year":"2015","journal-title":"Thorac Cardiovasc Surg Rep"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-0040-1701473","article-title":"Treatment of vascular thrombosis in antiphospholipid syndrome: an update","volume":"40","author":"L Kalmanti","year":"2020","journal-title":"Hamostaseologie"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-0039-1694789","article-title":"Therapie des antiphospholipid-syndroms (APS) mit DOAKs","volume":"39","author":"R Bauersachs","year":"2019","journal-title":"Hamostaseologie"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.autrev.2010.08.005","article-title":"Catastrophic antiphospholipid syndrome: updated diagnostic algorithms","volume":"10","author":"D Erkan","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2014-09-551978","article-title":"How I treat catastrophic thrombotic syndromes","volume":"126","author":"T L Ortel","year":"2015","journal-title":"Blood"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMcp1411910","article-title":"Clinical practice. Heparin-induced thrombocytopenia","volume":"373","author":"A Greinacher","year":"2015","journal-title":"N Engl J Med"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1055\/a-1223-3329","article-title":"Challenges in detecting clinically relevant heparin-induced thrombocytopenia antibodies","volume":"40","author":"T E Warkentin","year":"2020","journal-title":"Hamostaseologie"},{"issue":"09","key":"ref32","first-page":"1127","article-title":"[Heparin-induced thrombocytopenia]","volume":"51","author":"T Thiele","year":"2010","journal-title":"Internist (Berl)"},{"issue":"09","key":"ref33","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood-2017-04-778993","article-title":"Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review","volume":"130","author":"T E Warkentin","year":"2017","journal-title":"Blood"},{"issue":"22","key":"ref34","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"A Cuker","year":"2018","journal-title":"Blood Adv"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2021.05.018","article-title":"Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia","volume":"204","author":"T E Warkentin","year":"2021","journal-title":"Thromb Res"},{"issue":"22","key":"ref36","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"A Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"ref37","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"N H Schultz","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"ref38","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"M Scully","year":"2021","journal-title":"N Engl J Med"},{"issue":"08","key":"ref39","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jth.15362","article-title":"Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination","volume":"19","author":"S Platton","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17474086.2019.1636645","article-title":"High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review","volume":"12","author":"T E Warkentin","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/a-1469-7481","article-title":"Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH","volume":"41","author":"J Oldenburg","year":"2021","journal-title":"Hamostaseologie"},{"issue":"07","key":"ref42","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1111\/jth.15346","article-title":"Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)","volume":"19","author":"J Thaler","year":"2021","journal-title":"J Thromb Haemost"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2112974","article-title":"Vaccine-induced thrombocytopenia with severe headache","author":"F Salih","year":"2021","journal-title":"N Engl J Med"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1055\/a-1171-0473","article-title":"Current and future perspectives on ADAMTS13 and thrombotic thrombocytopenic purpura","volume":"40","author":"E Roose","year":"2020","journal-title":"Hamostaseologie"},{"issue":"10","key":"ref45","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"X L Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"M Scully","year":"2012","journal-title":"Br J Haematol"},{"issue":"05","key":"ref47","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1055\/s-0037-1616068","article-title":"Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation","volume":"86","author":"F B Taylor Jr","year":"2001","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2052-0492-2-15","article-title":"Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines","volume":"2","author":"H Wada","year":"2014","journal-title":"J Intensive Care"},{"issue":"03","key":"ref49","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jth.13230","article-title":"Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials","volume":"14","author":"Y Umemura","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1538-7836.2005.01697.x","article-title":"Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation","volume":"4","author":"J Kienast","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref51","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1111\/j.1538-7836.2004.00955.x","article-title":"Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation","volume":"2","author":"J F Dhainaut","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref52","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/jth.14578","article-title":"Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation","volume":"17","author":"T Iba","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ejh.12543","article-title":"Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review","volume":"95","author":"B Devalet","year":"2015","journal-title":"Eur J Haematol"},{"issue":"25","key":"ref54","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"A Hill","year":"2013","journal-title":"Blood"},{"issue":"04","key":"ref55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cyto.b.20525","article-title":"Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry","volume":"78","author":"M J Borowitz","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"issue":"10","key":"ref56","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/blood-2003-01-0009","article-title":"Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)","volume":"102","author":"C Hall","year":"2003","journal-title":"Blood"},{"issue":"10","key":"ref57","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood.2019003812","article-title":"How I treat paroxysmal nocturnal hemoglobinuria","volume":"137","author":"R A Brodsky","year":"2021","journal-title":"Blood"},{"issue":"S 01","key":"ref58","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/S0049-3848(20)30400-X","article-title":"Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia","volume":"191","author":"A Leader","year":"2020","journal-title":"Thromb Res"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1675-7824.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T18:56:00Z","timestamp":1699988160000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1675-7824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":58,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2022,2,23]]},"published-print":{"date-parts":[[2022,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1675-7824","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]}}}